Literature DB >> 11259444

The vesiculo-vacuolar organelle (VVO). A new endothelial cell permeability organelle.

A M Dvorak1, D Feng.   

Abstract

A newly defined endothelial cell permeability structure, termed the vesiculo-vacuolar organelle (VVO), has been identified in the microvasculature that accompanies tumors, in venules associated with allergic inflammation, and in the endothelia of normal venules. This organelle provides the major route of extravasation of macromolecules at sites of increased vascular permeability induced by vascular permeability factor/vascular endothelial growth factor (VPF/VEGF), serotonin, and histamine in animal models. Continuity of these large sessile structures between the vascular lumen and the extracellular space has been demonstrated in kinetic studies with ultrastructural electron-dense tracers, by direct observation of tilted electron micrographs, and by ultrathin serial sections with three-dimensional computer reconstructions. Ultrastructural enzyme-affinity cytochemical and immunocytochemical studies have identified histamine and VPF/VEGF bound to VVOs in vivo in animal models in which these mediators of permeability are released from mast cells and tumor cells, respectively. The high-affinity receptor for VPF/VEGF, VEGFR-2, was localized to VVOs and their substructural components by pre-embedding ultrastructural immunonanogold and immunoperoxidase techniques. Similar methods were used to localize caveolin and vesicle-associated membrane protein (VAMP) to VVOs and caveolae, indicating a possible commonality of formation and function of VVOs to caveolae.

Entities:  

Mesh:

Year:  2001        PMID: 11259444     DOI: 10.1177/002215540104900401

Source DB:  PubMed          Journal:  J Histochem Cytochem        ISSN: 0022-1554            Impact factor:   2.479


  59 in total

1.  Inhibition of kinin breakdown prolongs retention and action of bradykinin in a myocardial B2 receptor compartment.

Authors:  Andreas Dendorfer; Verena Folkers; Matthias Klinger; Sebastian Wolfrum; Peter Dominiak
Journal:  Br J Pharmacol       Date:  2003-01       Impact factor: 8.739

Review 2.  Role of reactive oxygen and nitrogen species in the vascular responses to inflammation.

Authors:  Peter R Kvietys; D Neil Granger
Journal:  Free Radic Biol Med       Date:  2011-11-12       Impact factor: 7.376

Review 3.  Endothelial cell heterogeneity.

Authors:  William C Aird
Journal:  Cold Spring Harb Perspect Med       Date:  2012-01       Impact factor: 6.915

Review 4.  Targeted endothelial nanomedicine for common acute pathological conditions.

Authors:  Vladimir V Shuvaev; Jacob S Brenner; Vladimir R Muzykantov
Journal:  J Control Release       Date:  2015-10-03       Impact factor: 9.776

Review 5.  Rho GTPases and leucocyte-induced endothelial remodelling.

Authors:  Jaime Millán; Anne J Ridley
Journal:  Biochem J       Date:  2005-01-15       Impact factor: 3.857

6.  An in vitro assay reveals a role for the diaphragm protein PV-1 in endothelial fenestra morphogenesis.

Authors:  Sofia Ioannidou; Katrin Deinhardt; Jadwiga Miotla; John Bradley; Eunice Cheung; Steven Samuelsson; Yin-Shan Ng; David T Shima
Journal:  Proc Natl Acad Sci U S A       Date:  2006-10-30       Impact factor: 11.205

Review 7.  Endothelial membrane reorganization during leukocyte extravasation.

Authors:  Natalia Reglero-Real; Beatriz Marcos-Ramiro; Jaime Millán
Journal:  Cell Mol Life Sci       Date:  2012-05-10       Impact factor: 9.261

8.  Endothelial alterations in a canine model of immune thrombocytopenia.

Authors:  Dana N LeVine; Rachel E Cianciolo; Keith E Linder; Petra Bizikova; Adam J Birkenheuer; Marjory B Brooks; Abdelghaffar K Salous; Shila K Nordone; Dwight A Bellinger; Henry Marr; Sam L Jones; Thomas H Fischer; Yu Deng; Marshall Mazepa; Nigel S Key
Journal:  Platelets       Date:  2017-11-28       Impact factor: 3.862

Review 9.  Cellular and molecular regulation of vascular permeability.

Authors:  Lauren M Goddard; M Luisa Iruela-Arispe
Journal:  Thromb Haemost       Date:  2013-02-07       Impact factor: 5.249

10.  Treatment of hemangioma by transfection of antisense VEGF gene.

Authors:  Shengguo Shan; Guang Shan; Duanlian Zhang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2009-06-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.